(Q40390611)

English

The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1 reference

based on heuristic

inferred from title

author name string

Coulibaly S

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Brühl P

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Mayrhofer J

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Schmid K

4

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Gerencer M

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Falkner FG

6

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

language of work or name

0 references

publication date

1 October 2005

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

341

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

91-101

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

The genomic sequence of ectromelia virus, the causative agent of mousepox

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

A monoclonal blocking-ELISA for detection of orthopoxvirus antibodies in feline sera

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Modified vaccinia virus Ankara induces moderate activation of human dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Fatal cowpox-like virus infection transmitted by cat.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Smallpox vaccination: Risk considerations for patients with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Neutralizing and protective antibodies directed against vaccinia virus envelope antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Duration of antiviral immunity after smallpox vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Smallpox as a Biological Weapon

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Antibody neutralization of the extracellular enveloped form of vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Vaccinia viruses with a serpin gene deletion and expressing IFN-gamma induce potent immune responses without detectable replication in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Developing new smallpox vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

The genomic sequence analysis of the left and right species-specific terminal region of a cowpox virus strain reveals unique sequences and a cluster of intact ORFs for immunomodulatory and host range proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

The formation and function of extracellular enveloped vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Characteristics of an attenuated vaccinia virus strain, LC16m0, and its recombinant virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Regulation of plaque size and host range by a vaccinia virus gene related to complement system proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

NYVAC: a highly attenuated strain of vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Clonal vaccinia virus grown in cell culture as a new smallpox vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

Construction of a vaccinia virus deficient in the essential DNA repair enzyme uracil DNA glycosylase by a complementing cell line

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

based on heuristic

inferred from DOI database lookup

Vaccinia virus gene D8 encodes a virion transmembrane protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.043

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2005.06.043

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40390611&oldid=1896758124"